Biocytogen Pharmaceuticals and Radiance Biopharma have signed an exclusive option and licence agreement for a bispecific antibody-drug conjugate (BsADC).
The partnership aims to advance the development, manufacture and commercialisation of a first-in-class fully human anti-human epidermal growth factor receptor-2 (HER2)/tumour-associated calcium signal transducer 2 (TROP2) BsADC for cancer treatments globally.
Radiance Biopharma will have the option to license Biocytogen鈥檚 ADC, targeting tumour-associated antigens HER2 and TROP2.
These antigens are frequently expressed and co-expressed by cancer types including non-small-cell lung cancer, breast and gastric cancers.
Radiance managing director and chairman of the board Marc Lippman stated: 鈥淲e are excited to enter into this exclusive option and licence agreement with Biocytogen for a novel human anti-HER2 and Trop2 bispecific antibody-drug conjugate.
鈥淧reclinical data from in vitro and in vivo assays of this BsADC shows promising high potency of anti-tumour activities in leading tumour indications. We are eager to work with Biocytogen to move the product to the clinic to benefit patients.鈥�
Upon Radiance exercising the option, Biocytogen will receive an option fee, licensing fee and payments related to development and commercial milestones. The deal also includes single-digit royalties on net sales.
Biocytogen president and CEO Dr Yuelei Shen stated: 鈥淲e are excited to collaborate with Radiance, a strong team with extensive experience in drug development, to develop a leading proprietary fully human bispecfic antibody-drug conjugate.
鈥淲e are optimistic that the combination of our strength in BsADC discovery and the extensive experience of Radiance鈥檚 team will help expedite the commercialisation of this dual-targeting BsADC.鈥�
In December 2023, Biocytogen signed an antibody agreement with Spanish biotech company Ona Therapeutics for the development of ADCs for solid tumours.
